TYK2 Kinase (Tyrosine Kinase 2)

A Janus kinase subtype that is involved in signaling from a broad variety of CYTOKINE RECEPTORS. The TYK2 kinase is considered the founding member of the janus kinase family and was initially discovered as a signaling partner for the INTERFERON ALPHA-BETA RECEPTOR. The kinase has since been shown to signal from several INTERLEUKIN RECEPTORS.

Also Known As:

Networked: 144 relevant articles (3 outcomes, 25 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Müller, Mathias: 8 articles (04/2021 - 01/2007)
2.	Strobl, Birgit: 6 articles (04/2021 - 03/2010)
3.	Banerjee, Subhashis: 5 articles (07/2022 - 10/2018)
4.	Thaçi, Diamant: 4 articles (07/2022 - 10/2018)
5.	Blauvelt, Andrew: 3 articles (07/2022 - 01/2021)
6.	Gooderham, Melinda: 3 articles (07/2022 - 10/2018)
7.	Morita, Akimichi: 3 articles (07/2022 - 10/2018)
8.	Papp, Kim A: 3 articles (07/2022 - 01/2021)
9.	Hirbe, Angela C: 3 articles (08/2021 - 01/2017)
10.	Shimoda, Kazuya: 3 articles (01/2017 - 12/2009)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 10/04/2018 - "Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis." 02/08/2023 - "Genetic linkage has related dysfunction of Tyrosine kinase 2 (Tyk2)-the first member of the Jak family that was described-to protection from psoriasis. " 01/01/2023 - "Genome-wide association studies (GWAS) have allowed identification of novel therapeutic targets in psoriasis including tyrosine kinase 2 (TYK2) where an exonic variant within the gene increases the risk of developing psoriasis. " 01/01/2022 - "Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis." 02/01/2023 - "Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors."
2.	Hepatocellular Carcinoma (Hepatoma) 10/01/2019 - "Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3β/Wnt/β-catenin signaling." 01/01/2022 - "We conducted a biopsy substudy during the randomized, double-blind, placebo-controlled first 24 weeks of a phase 2a clinical trial that evaluated the efficacy and safety of ritlecitinib, an inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family, and brepocitinib, an inhibitor of tyrosine kinase 2 (TYK2)/JAK1 in the treatment of AA. " 11/01/2022 - "The 24-week, double-blind period of the ALLEGRO phase 2a trial (NCT02974868) evaluated the safety and efficacy of ritlecitinib (Jak3/tyrosine kinase expressed in the hepatocellular carcinoma inhibitor) and brepocitinib (tyrosine kinase 2/Jak1 inhibitor) in patients with alopecia areata; patients could subsequently continue treatment in a 24-week single-blind extension, followed by a crossover open-label extension, described in this article. "
3.	Alopecia Areata 11/01/2022 - "The 24-week, double-blind period of the ALLEGRO phase 2a trial (NCT02974868) evaluated the safety and efficacy of ritlecitinib (Jak3/tyrosine kinase expressed in the hepatocellular carcinoma inhibitor) and brepocitinib (tyrosine kinase 2/Jak1 inhibitor) in patients with alopecia areata; patients could subsequently continue treatment in a 24-week single-blind extension, followed by a crossover open-label extension, described in this article. "
4.	Infections 01/01/2016 - "In the absence of type I IFN treatment, SAV3 downregulated several Jak/stat pathway genes that included type I and II receptor genes, Jak2, tyrosine kinase 2 (Tyk2), Stat3 and Stat5 pointing to possible failure to activate the Jak/stat signaling pathway and inhibition of signal transducers caused by SAV3 infection. " 06/01/2014 - "Tyrosine kinase 2 (TYK2) has a pivotal role in immunity to infection and tumor surveillance. " 01/01/2011 - "In this study, we showed that infection of airway epithelial cells with hMPV decreased cellular level of Janus tyrosine kinase (Jak1) and tyrosine kinase 2 (Tyk2), due to enhanced proteosomal degradation and reduced gene transcription. " 02/01/2009 - "Recent studies have demonstrated that hypomorphic mutations in signal transducer and activator of transcription 3 result in the classical multisystem form of HIES, whereas a null mutation in tyrosine kinase 2 causes the autosomal recessive form of HIES that is associated with viral and mycobacterial infections. " 09/01/2004 - "Furthermore, JEV infection blocked the tyrosine phosphorylation of IFN receptor-associated Jak kinase, Tyk2, without affecting the expression of IFN-alpha/beta receptor on the cell surface. "
5.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 06/01/2007 - "This is a family-based association study to investigate the genetic contribution of tyrosine kinase 2 (TYK2 ) to disease susceptibility in 380 UK systemic lupus erythematosus (SLE) families, consisting of parents and affected offspring. " 01/01/2023 - "Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial." 06/01/2007 - "We defined a 2.8 kb core association region in TYK2, between these two variants, which narrows down the 5.7 kb gap in the study by Sigurdsson et al. (Sigurdsson S, Nordmark G, Goring HH et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. " 01/01/2023 - "Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition." 01/01/2009 - "Tyrosine kinase 2 (TYK2) is a type I interferon (IFN) signaling pathway gene and was previously reported to be a risk factor for systemic lupus erythematosus (SLE) in Caucasian populations. "

Related Drugs and Biologics

1.	deucravacitinib
2.	Protein-Tyrosine Kinases (Tyrosine Kinase)
3.	apremilast
4.	frovatriptan (Allegro)
5.	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
6.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
7.	Interferon Regulatory Factors
8.	ErbB Receptors (EGF Receptor)
9.	Toll-Like Receptor 4
10.	Mitogen-Activated Protein Kinases

Related Therapies and Procedures

1.	Therapeutics
2.	Intravitreal Injections
3.	Phototherapy (Light Therapy)